
Xtrackers MSCI World ex USA UCITS ETF 1C (EXUS.L)
This fund copies the MSCI World ex USA index to give you instant access to large and medium companies in developed countries outside the US.
Is Xtrackers MSCI World ex USA UCITS ETF 1C a good fund for a UK beginner?
The honest version: This fund copies the MSCI World ex USA index to give you instant access to large and medium companies in developed countries outside the US.
Over about 2 years to 2026-07-15. This already includes the fund's dividends, which an accumulating fund reinvests for you. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
This is a fund, so it moves with its whole basket (Global) - not any single company's news. One share having a bad day barely shows up here.
What does Xtrackers MSCI World ex USA UCITS ETF 1C do?
The fund tracks the MSCI World ex USA index, holding companies from wealthy nations around the globe while strictly leaving out the United States. With one simple purchase, your money is spread across major global names like ASML, HSBC, and Nestlé, cutting across sectors such as banking, engineering, and healthcare. The ongoing charge is 0.15% a year, which means the fund manager quietly takes about £1.50 annually for every £1,000 you have invested to cover running costs. Dividends are automatically accumulating, meaning any cash payouts from the companies are rolled right back inside the fund to pick up more assets without you having to lift a finger.
Holds large and medium companies from developed countries outside the United States, often used to balance a US-heavy portfolio.
What's actually inside this fund?
This fund deliberately holds no US companies - it's the developed world minus the United States, often used to balance a US-heavy portfolio.
Its 10 biggest holdings
- 1ASML Holding NV3.1%
- 2HSBC Holdings PLC1.3%
- 3Roche Holding AG Ordinary Shares new1.2%
- 4Royal Bank of Canada1.2%
- 5Novartis AG Registered Shares1.2%
- 6AstraZeneca PLC1.1%
- 7Nestle SA1.1%
- 8Siemens AG1.0%
- 9Shell PLC0.9%
- 10Tokyo Electron Ltd0.9%
The top 10 add up to about 13% of the fund. The rest is spread thinly across the fund's many other holdings.
By sector
- Financials27%
- Industrials18%
- Technology12%
- Healthcare9%
- Consumer cyclical7%
- Materials7%
- Consumer staples6%
- Energy5%
Top holdings and sector split from the fund's published data as of the figures date - they drift over time as the fund and the index change.
- Provides broad international diversification outside the US market
- Low ongoing cost of 0.15% a year
- Simple one-fund exposure to thousands of developed-market businesses
- Automatically reinvests dividends to grow the investment quietly
- The fund value falls whenever its underlying global markets fall
- Does not include any exposure to the US stock market
- Subject to currency swings between British pounds and foreign currencies
- Heavy exposure to financial services and industrial sectors
More in Global
What are the pros and cons of Xtrackers MSCI World ex USA UCITS ETF 1C?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Provides broad international diversification outside the US market
- Low ongoing cost of 0.15% a year
- Simple one-fund exposure to thousands of developed-market businesses
- Automatically reinvests dividends to grow the investment quietly
- The fund value falls whenever its underlying global markets fall
- Does not include any exposure to the US stock market
- Subject to currency swings between British pounds and foreign currencies
- Heavy exposure to financial services and industrial sectors
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.